- Navidea Biopharmaceuticals (NYSE:NAVB) has signed a deal to provide Meilleur Technologies, a wholly owned subsidiary of Cerveau Technologies, worldwide rights to conduct research using NAV4694, as well as an exclusive license for the commercialization of NAV4694 in Australia, Canada, China, and Singapore.
- As a result of the agreement, the litigation initiated by Beijing Sinotau Medical Research Co., will be dismissed.
- NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate intended for use in Positron Emission Tomography imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s disease.
- Shares are up 10% premarket.